Skip to main content

Advertisement

Table 5 Characterisitics of patients and corresponding PDXs

From: Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

  Clinical history Prior treatment Days to initial tumor growth Cell line generation
TKO-001 PDX from biopsy specimens of hepatic metastasis in a 72-year-old hispanic male Surgical resection cisplatin and etoposide with good response Platinum sensitive recurrence retreated with platinum/etoposide salvage therapy with irinotecan 335 No
TKO-002 PDX from biopsy of hepatic metastasis from a female white patient Frontline carboplatin/etoposide with tumor response after two cycles and progression after the fourth cycle Single agent etoposide Topotecan 49 Yes
TKO-003 PDX from bronchoscopic biopsy samples obtained from a paratracheal mass and subcarinal lymph node metastasis in a 71-year-old African American male Initial diagnosis of limited stage SCLC treated with combined radiation and cisplatin/etoposide. Following recurrence 2 years later of his platinum sensitive disease, he was retreated with carboplatin/etoposide and more recently was treated with topotecan prior to study enrollment 135 No
TKO-004    No growth No
TKO-005 PDX developed using bronchoscopic biopsy samples obtained from a left lower lung nodule in a 50 year old African American male Previously treated with combined radiation and cisplatin/etoposide for limited stage SCLC. Patient had disease progression more than 6 months after completion of chemoradiation and had no other systemic therapy prior to coming on this clinical trial when the biopsy was obtained to generate the PDX 103 No
TKO-006    No growth No
TKO-007    No growth No
TKO-008 PDX generated using lung biopsy from a 76-year-old male Caucasian patient Previously treated with carboplatin/etoposide for six cycles. He subsequently received paclitaxel for progressive disease that occurred 4 months after completing frontline therapy 239 No
TKO-009    No growth No